Kyntra Bio, Inc. (KYNB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kyntra Bio, Inc. (KYNB) trades at $7.48 with AI Score 27/100 (Grade F). Kyntra Bio, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics. Market cap: $30.28M, Sector: Healthcare.
Price live · AI analysis from May 4, 2026Analyst Coverage for KYNB: KYNB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KYNB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
KYNB: 1/1 perspectives are bearish.
How is this calculated? →Kyntra Bio, Inc. (KYNB) Healthcare & Pipeline Overview
Kyntra Bio, Inc., founded in 1993, is a biopharmaceutical company focused on developing novel therapeutics for anemia, fibrotic disease, and cancer. Utilizing hypoxia-inducible factor and connective tissue growth factor biology, Kyntra Bio aims to commercialize innovative medicines, operating within the competitive healthcare landscape from its San Francisco headquarters.
What Is the Investment Thesis for KYNB?
Kyntra Bio, Inc. presents a focused investment opportunity within the biopharmaceutical sector, targeting anemia, fibrotic disease, and cancer. The company's expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology is a key value driver. With a P/E ratio of 0.2 and a profit margin of 2848.2%, the company shows potential for high returns, although these metrics should be viewed cautiously given the inherent risks in the biopharmaceutical industry. Upcoming catalysts include the progression of drug candidates through clinical trials and potential partnerships for commercialization. The company's gross margin of 75.8% indicates efficient operations. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's ability to successfully navigate these challenges will be crucial for long-term growth and investor returns.
Based on FMP financials and quantitative analysis
KYNB Key Highlights
- Market Cap of $30.28M reflects its position as a smaller player in the biopharmaceutical industry.
- P/E Ratio of 0.2 suggests the company is potentially undervalued, but requires careful evaluation due to the volatile nature of the biotech sector.
- Profit Margin of 2848.2% indicates high profitability, but may be influenced by specific accounting factors or one-time events.
- Gross Margin of 75.8% demonstrates efficient cost management in the production of its therapeutics.
- Beta of 0.90 suggests the stock is slightly less volatile than the overall market.
Who Are KYNB's Competitors?
KYNB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 83 |
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| YI 111, Inc. | $4.13 | -0.12% | $36.04M | 44 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KYNB's Key Strengths?
- Specialized expertise in HIF and CTGF biology.
- Innovative approach to drug discovery and development.
- High profit margin of 2848.2%.
- Gross Margin of 75.8%.
What Are KYNB's Weaknesses?
- Limited financial resources compared to larger pharmaceutical companies.
- Dependence on successful clinical trial outcomes.
- Small market capitalization of $30.28M.
- Limited commercialization infrastructure.
What Could Drive KYNB Stock Higher?
- Results from Phase 2 clinical trials for lead drug candidate in Q3 2026.
- Strategic partnerships for commercialization of pipeline products.
- Expansion of research and development efforts into new therapeutic areas.
What Are the Key Risks for KYNB?
- Financial-distress signal — its Altman Z-Score of -22.68 sits in the distress zone (elevated bankruptcy risk).
- Clinical trial failures and regulatory setbacks.
- Competition from established pharmaceutical companies.
- Dependence on securing funding for research and development.
- Patent expiration and generic competition.
What Are the Growth Opportunities for KYNB?
- Expansion into New Therapeutic Areas: Kyntra Bio can leverage its expertise in HIF and CTGF biology to expand its pipeline into new therapeutic areas beyond anemia, fibrotic disease, and cancer. This could involve targeting other diseases where these pathways play a significant role, such as cardiovascular disease or neurodegenerative disorders. The market for therapies targeting these conditions is substantial, offering significant growth potential. Success in this area would require further research and development, as well as strategic partnerships to broaden its expertise and resources. Timeline: 3-5 years.
- Strategic Partnerships and Collaborations: Kyntra Bio can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. These partnerships can provide access to funding, expertise, and established distribution networks. The market for pharmaceutical collaborations is highly competitive, but Kyntra Bio's innovative approach to HIF and CTGF biology could make it an attractive partner. Timeline: Ongoing.
- Advancement of Clinical Trials: The successful advancement of Kyntra Bio's drug candidates through clinical trials is a critical growth opportunity. Positive clinical trial results can significantly increase the value of the company and attract further investment. The clinical trial process is lengthy and expensive, but it is essential for demonstrating the safety and efficacy of new therapies. Timeline: Ongoing.
- Geographic Expansion: Kyntra Bio can expand its geographic reach by seeking regulatory approval and commercializing its products in new markets. This could involve targeting countries with high unmet medical needs in anemia, fibrotic disease, and cancer. Geographic expansion requires careful planning and execution, as well as an understanding of local regulatory requirements and market dynamics. Timeline: 2-4 years.
- Acquisition of Complementary Technologies: Kyntra Bio can acquire complementary technologies or companies to enhance its research and development capabilities and broaden its product pipeline. This could involve acquiring companies with expertise in drug delivery, diagnostics, or other areas that align with its strategic goals. The market for biotechnology acquisitions is active, with numerous opportunities for companies to expand their capabilities through strategic acquisitions. Timeline: 1-3 years.
What Opportunities Does KYNB Have?
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Advancement of drug candidates through clinical trials.
- Geographic expansion into new markets.
What Threats Does KYNB Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Patent expiration and generic competition.
What Are KYNB's Competitive Advantages?
- Proprietary knowledge of HIF and CTGF biology.
- Patent protection on novel therapeutic compounds.
- First-mover advantage in targeting specific disease pathways.
What Does KYNB Do?
Founded on September 29, 1993, by Thomas B. Neff, Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. The company is dedicated to the discovery, development, and commercialization of novel therapeutics, primarily focusing on addressing unmet medical needs in anemia, fibrotic disease, and cancer. Kyntra Bio leverages its expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to create innovative medicines. Kyntra Bio's research and development efforts are centered on understanding and modulating the HIF and CTGF pathways, which play critical roles in various disease processes. By targeting these pathways, the company aims to develop therapies that can effectively treat a range of conditions. The company's approach involves identifying promising drug candidates, conducting preclinical studies to evaluate their safety and efficacy, and advancing them through clinical trials. Kyntra Bio operates within the highly competitive biopharmaceutical industry, facing competition from both large pharmaceutical companies and smaller biotechnology firms. The company's success depends on its ability to develop and commercialize innovative therapies that offer significant clinical benefits over existing treatments. Kyntra Bio's commitment to scientific excellence and its focus on specific therapeutic areas position it to make meaningful contributions to the treatment of anemia, fibrotic disease, and cancer.
What Products and Services Does KYNB Offer?
- Discovers novel therapeutics for various diseases.
- Develops medicines targeting anemia, fibrotic disease, and cancer.
- Commercializes innovative treatments for unmet medical needs.
- Focuses on hypoxia-inducible factor (HIF) biology.
- Targets connective tissue growth factor (CTGF) biology.
- Conducts preclinical studies to evaluate drug safety and efficacy.
- Advances drug candidates through clinical trials.
How Does KYNB Make Money?
- Develops and patents novel therapeutic compounds.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments and royalties on partnered products.
What Industry Does KYNB Operate In?
Kyntra Bio, Inc. operates within the medical-pharmaceuticals industry, a sector characterized by intense research and development, regulatory scrutiny, and high financial risk. The industry is driven by the constant need for innovative therapies to address unmet medical needs. Kyntra Bio's focus on anemia, fibrotic disease, and cancer places it in direct competition with both large pharmaceutical companies and smaller biotechnology firms. The company's success depends on its ability to navigate the complex regulatory landscape, secure funding for research and development, and successfully commercialize its drug candidates. The global pharmaceuticals market is projected to reach trillions of dollars by 2026, reflecting the significant growth potential within the industry.
Who Are KYNB's Key Customers?
- Patients suffering from anemia.
- Patients suffering from fibrotic diseases.
- Patients suffering from cancer.
- Healthcare providers prescribing treatments.
KYNB Valuation & Market Position
With a $30.28M market cap, Kyntra Bio, Inc. sits in the micro-cap segment of the market. Relative to its peer group, KYNB's quantitative score of 27/100 is below the peer average of 78/100.
FY2026 estForward Outlook
Wall Street analysts project Kyntra Bio, Inc. revenue of about $7.9M for fiscal 2026, with EPS near $-13.89.
F-Score 6/9Financial Health
Kyntra Bio, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -22.68 places it in the distress zone, a signal of elevated financial risk.
P/E 0.2Key Financial Metrics
KYNB trades at a trailing price-to-earnings ratio of 0.16, below the Healthcare sector average of ~23x. Its free cash flow yield is -71.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.61 indicates the company holds enough short-term assets to cover its near-term obligations.
KYNB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Kyntra Bio's recent insider buying suggests those in the know see long-term value, mirroring moves seen before other biotech breakouts. Community sentiment is cautiously optimistic, with many believing their pipeline has untapped potential. Recent market developments favor companies with innovative drug delivery systems, which aligns with Kyntra's focus. There's a growing perception that Kyntra is undervalued compared to peers with similar clinical trial stages.
Bear Case
- Recent community discussions highlight concerns about Kyntra's cash burn rate and potential future dilution, a common fear in the biotech sector. Some insiders sold shares earlier in the year, creating mixed signals despite recent purchases. Market perception is that regulatory hurdles could delay Kyntra's drug approvals, similar to setbacks faced by other companies. There's a bearish view that Kyntra's current pipeline is too narrow and lacks diversification, increasing risk.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
KYNB Latest News
-
Earnings Scheduled For May 11, 2026
benzinga · May 11, 2026
KYNB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KYNB.
Price Targets
Wall Street price target analysis for KYNB.
KYNB MoonshotScore
What does this score mean?
The MoonshotScore rates KYNB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Thane Wettig
CEO
Thane Wettig serves as the CEO of Kyntra Bio, Inc., bringing extensive experience in the biopharmaceutical industry. His background includes leadership roles in both research and development and commercial operations. Wettig has a proven track record of driving innovation and building successful teams. He holds advanced degrees in molecular biology and business administration, providing him with a strong foundation in both the scientific and business aspects of the pharmaceutical industry.
Track Record: Under Thane Wettig's leadership, Kyntra Bio has focused on advancing its pipeline of novel therapeutics for anemia, fibrotic disease, and cancer. He has overseen the company's strategic partnerships and collaborations, as well as its efforts to secure funding for research and development. Wettig has also emphasized the importance of scientific excellence and innovation in driving the company's growth.
Common Questions About KYNB (Healthcare)
What does Kyntra Bio, Inc. do?
Kyntra Bio, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for anemia, fibrotic disease, and cancer. The company leverages its expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to create innovative medicines. Kyntra Bio's business model involves developing and patenting novel therapeutic compounds, and then out-licensing or partnering with larger pharmaceutical companies for commercialization. The company generates revenue through milestone payments and royalties on partnered products.
What do analysts say about KYNB stock?
Analyst coverage of Kyntra Bio, Inc. is limited, reflecting its small market capitalization and early stage of development. Key valuation metrics include its P/E ratio of 0.2 and gross margin of 75.8%. Growth considerations include the successful advancement of its drug candidates through clinical trials and the potential for strategic partnerships. However, analysts also note the risks associated with clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The consensus view is cautiously optimistic, pending further clinical and regulatory developments. No buy/sell recommendations are made.
What are the main risks for KYNB?
The main risks for Kyntra Bio, Inc. include clinical trial failures, which could significantly impact the value of its drug candidates. Regulatory hurdles and delays could also impede the company's progress in bringing its products to market. Competition from established pharmaceutical companies with greater resources and expertise is another significant risk. Additionally, patent expiration and the emergence of generic competition could erode the company's market share and profitability. Securing funding for research and development is an ongoing risk, particularly given the capital-intensive nature of the biopharmaceutical industry.
How does Kyntra Bio, Inc. manage patent expiration risks?
Kyntra Bio, Inc. manages patent expiration risks through a multi-faceted approach that includes continually innovating to develop new generations of therapeutics, strategically extending patent protection through formulations and combinations, and actively monitoring the competitive landscape for potential biosimilar threats. The company also focuses on building a robust intellectual property portfolio to protect its core technologies and maintain a competitive advantage in the market. Lifecycle management strategies are crucial for sustaining long-term revenue streams and mitigating the impact of patent cliffs.
What are the key growth opportunities for KYNB in healthcare?
Kyntra Bio, Inc. has several key growth opportunities within the healthcare sector. These include expanding into new therapeutic areas by leveraging its expertise in HIF and CTGF biology, pursuing strategic partnerships and collaborations with larger pharmaceutical companies to accelerate drug development and commercialization, and advancing its drug candidates through clinical trials to demonstrate their safety and efficacy. Additionally, geographic expansion into new markets and the acquisition of complementary technologies can further drive growth and enhance the company's competitive position.
What are the key factors to evaluate for KYNB?
Kyntra Bio, Inc. (KYNB) holds an AI score of 27/100 (low). P/E: 0.2x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does KYNB data refresh on this page?
KYNB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven KYNB's recent stock price performance?
Kyntra Bio, Inc. (KYNB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in HIF and CTGF biology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- Analyst opinions are based on limited coverage and may not reflect all perspectives.
- The biopharmaceutical industry is inherently risky, and investment decisions should be made with caution.